Medison Issues Presentation to Knight Shareholders

Makes Case for Urgent Change, Improved Governance and a Common-Sense Strategic Growth PlanDetails History of Failed Execution, Underperformance and Conflicts of Interest Under Current Board and CEOProvides Background on Experienced, Independent Director Nominees That...

read more

Knight Therapeutics’ Second Largest Shareholder Presents Strategy to Create Shareholder Value

Medison Biotech Ltd. (“Medison”), which together with its affiliates owns more than 10.4 million shares, or 7.3% of Knight Therapeutics, Inc.(TSX:GUD) (“Knight”or the “Company”) has presented a detailed and compelling plan to the Company’s Board of Directors. The primary objective of the plan is to create value for all of Knight’s shareholders by creating a leading “rest of world” (“ROW”) pharmaceutical company that focuses on commercializing highly innovative biotech products.

read more

Stay Informed

Enter your info below to stay up-to-date.